|
Advertising
Customer Service
Register
|
MORE FROM NJBIZ
PEOPLE WHO READ THIS...
Also read these stories:
|
|||||||||
By Shankar P.In mid-September, Johnson also was named head of the oncology business unit at Eli Lilly, the Indianapolis, Ind.-based pharmaceutical giant that bought ImClone last October for $6.5 billion. Johnson moved to head ImClone two years ago from Johnson & Johnson, where he was group chairman of its worldwide pharmaceutical business.
BioNJ’s Dr. Sol J. Barer Award for Vision, Innovation and Leadership is named after the chairman and CEO of Celgene Corp., of Summit, a large biotechnology company with a market capitalization of more than $25 billion. Earlier recipients of the award include Sol Barer and Lisa Drakeman, CEO of Princeton’s Genmab.
E-mail Shankar P. at shankar_p@njbiz.com